The current standard of care for prostate cancer can sometimes cease to be effective, causing the cancer to worsen. The TRITON2 and TRITON3 studies are looking at the PARP inhibitor, rucaparib, in the treatment of prostate cancer with BRCA1 and BRCA2 mutations. In addition, the TRITON trials are employing the use of genomic screening of plasma, which can provide valuable information as it is often difficult to obtain biopsies in patients with prostate cancer. At ESMO 2018, Dr Josep M Piulats talked to us about the TRITON studies, how the preliminary data are already helping select patients who will benefit from rucaparib, how these trials will affect clinical practice, and future research.
1. Could you tell us a little about the mechanism of action of rucaparib and the rationale for using it in the treatment of metastatic castration-resistant prostate cancer? (0:11)
2. What have been the major findings from the data of the TRITON2 study? (1:36)
3. What were the findings of your recent study involving genomic screening of plasma ctDNA and tissue samples in TRITON2 and TRITON3? (2:37)
4. What are the clinical implications of these findings? (3:49)
5. What are the next steps in this area of research over the coming years? (4:56)
Speaker disclosures: Josep M Piulats has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Prostate Cancer
ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]
Arnulf Stenzl: Highlights from EAU23!
touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]